The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Real-world analysis of Hodgkin lymphoma outcomes after auto-SCT
Ali Bazarbachi, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the evolution of outcomes over time for relapsed Hodgkin lymphoma (HL) after autologous stem cell transplantation (auto-SCT). Real-world data from 1781 HL patients in the European Blood and Marrow Transplant (EBMT) registry was analyzed to assess the prognosis of patients with recurrent-HL post-auto-SCT. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
